Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea

Exclusion Criteria

• •History of narcolepsy.
• •Clinically significant craniofacial malformation.
• •Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or cardiac failure) or hypertension requiring more than 2 medications for control. A medication for these purposes is defined by dosage form, such that a combination antihypertensive medication is considered 1 medication
• •CPAP should not be used for at least 2 weeks prior to first study PSG
• •History of using oral or nasal devices for the treatment of OSA may enroll as long as the devices are not used during participation in the study.